Treatment of Erythema Multiforme in a 9-Year-Old
The appropriate treatment for a 9-year-old with erythema multiforme is primarily supportive care with symptomatic management using topical steroids or antihistamines, combined with identification and treatment of the underlying trigger—most commonly herpes simplex virus or Mycoplasma pneumoniae infection 1, 2, 3.
Initial Assessment and Trigger Identification
First, distinguish erythema multiforme from the more serious Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Erythema multiforme presents with typical target lesions starting on acral surfaces (hands, feet) and progressing proximally, with patients typically remaining constitutionally well 4. In contrast, SJS/TEN shows widespread erythematous or purpuric macules with blisters and significant systemic involvement 3.
Key Diagnostic Features:
- Target-like lesions fixed for minimum 7 days (versus urticaria which resolves within 24 hours) 3
- Symmetric distribution on extremities, especially extensor surfaces 3
- May involve oral mucosa (erythema multiforme major) but patients remain relatively well 4
Identify the Trigger:
Immediately rule out Mycoplasma pneumoniae infection, as this requires antibiotic treatment 1. In pediatric cases:
- Infections account for the majority: HSV (17.9%) and M. pneumoniae (15.7%) are most common 2
- Drugs account for 24.1% of cases 2
- Consider recent vaccinations (3.2% of cases) 2
Treatment Algorithm
1. Supportive Care (First-Line for All Cases)
This was the sole treatment in 31.1% of pediatric cases 2:
- Topical corticosteroids for skin lesions 3
- Antihistamines for pruritus 3
- Pain management
- Maintain hydration and nutrition
2. Etiologic Treatment Based on Trigger
If Mycoplasma pneumoniae suspected or confirmed:
- Macrolide antibiotics (used in 7.7% of pediatric cases) 2
- This is the only scenario requiring immediate specific antimicrobial therapy 1
If HSV-related:
- Consider antivirals (used in 14.6% of cases) 2
- For recurrent HSV-associated EM (occurs in 61% of recurrent cases), prophylactic antiviral therapy is indicated 2, 3
If drug-induced:
- Stop the offending medication immediately 4
3. Systemic Corticosteroids: Controversial
The evidence on systemic corticosteroids is mixed and debatable 5:
- Used in 19.8% of pediatric cases 2
- One case report advocates for their use in HSV-associated EM 6
- However, no randomized studies clearly indicate which children benefit from this treatment 5
- For mild EM, there is no indication for steroids 5
My recommendation: Reserve systemic corticosteroids for severe mucosal involvement causing significant pain and impaired oral intake, but recognize this is not evidence-based.
4. Severe Cases Requiring Hospitalization
Hospitalize if:
- Severe mucosal involvement preventing adequate oral intake 3
- Need for intravenous fluids and electrolyte repletion 3
- Diagnostic uncertainty with SJS/TEN 4
Important Clinical Pitfalls
Do not confuse EM with SJS/TEN: EM does not progress to SJS/TEN, has better prognosis, and requires different management 4
Do not miss M. pneumoniae: This is the only trigger requiring specific antibiotic treatment 1
Recognize recurrence risk: 14.3% of pediatric EM is recurrent, most commonly HSV-related (61% of recurrent cases) 2. At age 9, this child is at higher risk for recurrence than infants 2
Long-term sequelae are rare (1.3%) 2, providing reassurance for families
Prognosis
Mild EM is self-limited and resolves in 2-4 weeks 5. The mortality and severe complications seen in SJS/TEN do not apply to true erythema multiforme 4. Patients typically make a good recovery and are rarely affected by long-term complications 4.